$PEL Piramal’s Pharma segments segments seems to be able to clear FDA and customer audits more regularly compared to its peers in India. Would be interested in what other participants think. This is driven by….
— Beowulf (@beowulfcapital) August 12, 2018
Beowulf Capital 